An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

NCT04670770 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuromyelitis Optica Spectrum Disorders

Interventions

DRUG: Drug - SHR1459

Sponsor

Reistone Biopharma Company Limited